Uncommon epidermal growth factor receptor (EGFR) mutations collectively account for 10%
of EGFR mutations, harboring heterogeneous molecular alterations within exons 18–21 with …

Abstract Objective Exon 19 deletion (19del) is a sensitive mutation of epidermal growth
factor receptor (EGFR) observed in non-small cell lung cancer (NSCLC), and consists of a …

Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancers (NSCLC)
driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain …

Although we have experienced some cases with discordant results between the Oncomine
Dx target test (ODxTT) and conventional single gene tests for detecting EGFR alterations …

Objective Panel-based next-generation sequencing (NGS) is increasingly used for the
diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk …

Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung
cancer patients: a narrative review - PMC Back to Top Skip to main content NIH NLM Logo …

Purpose: The uncommon EGFR exon 19 deletion (ex19del), L747_A750> P, demonstrates
reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in …

Osimertinib is an irreversible EGFR inhibitor registered for advanced NSCLC patients whose
tumors harbor recurrent somatic activating mutations in EGFR (EGFRm+) or the frequently …

Background The study investigated the resistant pattern and clinical outcomes of epidermal
growth factor receptor (EGFR) exon 19 deletion (19del) subtypes to tyrosine kinase …

Background The aim of this study was to investigate the clinical features,
immunohistochemistry (IHC), compound mutation, and prognosis of patients with non-small …